Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.54 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29198147 | 0.85 | CHRM1 (0.53) | OPRM1GPR119CCR5CHRM2CHRM4 | |
| SCHEMBL6577909 | 0.85 | CHRM1 (0.56) | OPRM1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14146573 | 0.85 | CCR5 (0.51) | CCR5CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8047936 | 0.85 | HSD11B1 (0.60) | OPRM1CCR5CHRM2CHRM4CHRM5 | |
| SCHEMBL318475 | 0.85 | HSD11B1 (0.60) | OPRM1CCR5CHRM1 | |
| SCHEMBL28706708 | 0.85 | CCR5 (0.51) | OPRM1CCR5CHRM2CHRM4CHRM5 | |
| SCHEMBL30870565 | 0.85 | HSD11B1 (0.60) | OPRM1CCR5CHRM2CHRM4CHRM5 | |
| SCHEMBL4443186 | 0.84 | HSD11B1 (0.52) | GPR119CCR5CHRM2CHRM4CHRM5 | |
| SCHEMBL22587911 | 0.84 | HSD11B1 (0.56) | OPRM1CCR5CHRM2CHRM4CHRM5 | |
| SCHEMBL4434708 | 0.84 | CCR5 (0.53) | CCR5CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | OPRM1 4069/4885GPR119 189/4885CCR5 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.